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Autonomic function in amnestic 
and non‑amnestic mild cognitive 
impairment: spectral heart rate 
variability analysis provides 
evidence for a brain–heart axis
paola nicolini1*, Daniela Mari2, carlo Abbate2,3, Silvia inglese2, Laura Bertagnoli2, 
emanuele tomasini2,3, paolo D. Rossi2 & federico Lombardi1
Mild cognitive impairment (Mci) is a heterogeneous syndrome with two main clinical subtypes, 
amnestic (aMci) and non‑amnestic (naMci). the analysis of heart rate variability (HRV) is a tool to 
assess autonomic function. cognitive and autonomic processes are linked via the central autonomic 
network. Autonomic dysfunction entails several adverse outcomes. However, very few studies have 
investigated autonomic function in Mci and none have considered Mci subtypes or the relationship 
of HRV indices with different cognitive domains and structural brain damage. We assessed autonomic 
function during an active orthostatic challenge in 253 oupatients aged ≥ 65, [n = 82 aMCI, n = 93 naMCI, 
n = 78 cognitively normal (CN), neuropsychologically tested] with power spectral analysis of HRV. We 
used visual rating scales to grade cerebrovascular burden and hippocampal/insular atrophy (HA/iA) on 
neuroimaging. only aMci showed a blunted response to orthostasis. postural changes in normalised 
low frequency (Lf) power and in the Lf to high frequency ratio correlated with a memory test 
(positively) and HA/iA (negatively) in aMci, and with attention/executive function tests (negatively) 
and cerebrovascular burden (positively) in naMci. these results substantiate the view that the AnS 
is differentially impaired in aMCI and naMCI, consistently with the neuroanatomic substrate of 
Alzheimer’s and small‑vessel subcortical ischaemic disease.
Mild cognitive impairment (MCI) is a condition characterised by minor cognitive deficits, without substantial 
impairment in the activities of daily living, and it represents an intermediate, pre-dementia stage lying along the 
continuum from normal cognitive ageing to  dementia1. With the ageing  demographic2, MCI is set to become a 
major public health issue.
It has been increasingly recognised that MCI is a heterogeneous syndrome that can be classified into two main 
clinical subtypes, amnestic MCI (aMCI) and non-amnestic MCI (naMCI), based on whether or not memory is 
impaired. There is a prevalent agreement, although with some  controversy3, that they reflect different underly-
ing aetiologies and prognoses, with aMCI regarded as a prodromal form of Alzheimer’s disease (AD) dementia 
and naMCI most likely to progress to non-AD  dementias4,5. In particular, even if naMCI can evolve to fronto-
temporal dementia (FTD) and Lewy body dementia (LBD), there is a growing consensus for a strong association 
with cerebrovascular disease and vascular dementia (VAD)5,6. VAD is the second most common dementia in 
older people after AD and its subcortical form, due to cerebral small-vessel disease, is the most frequent and 
clinically homogeneous type of  VAD7 and the one most likely to be preceded by  MCI8.
Heart rate variability (HRV) is the physiological phenomenon by which the heart rate changes from beat to 
beat, producing oscillations in the time intervals between consecutive R waves (RR intervals) on an electrocar-
diographic (ECG) recording and it reflects the influence on sinus node activity of the two limbs of the autonomic 
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nervous system (ANS), sympathetic and  parasympathetic9. HRV analysis therefore provides a simple and reliable 
method for the assessment of autonomic function and has been extensively used in clinical  research10.
Cognitive and autonomic processes are linked via the central autonomic network (CAN), which is involved 
both in cognition and in the autonomic regulation of cardiovascular  function11. The CAN consists of a complex 
network of cortical and subcortical regions—including the insula, hippocampus and prefrontal cortex—which 
projects to the preganglionic neurons of the ANS. Thus, the CAN has been widely identified as the neuroanatomic 
substrate of a brain–heart  axis11,12.
A relationship between cognitive functioning and HRV has been demonstrated in large cohorts of older 
 individuals13–15 as well as in smaller samples of subjects affected by dementia, mainly AD  dementia16. Despite the 
potential clinical relevance of autonomic dysfunction in MCI—in terms of syncope/falls17, cognitive  decline15 
and  mortality10—very few studies have evaluated HRV in  MCI18–21, and none of these have categorised MCI in 
aMCI and naMCI.
In the current study we hypothesised that the autonomic response to active standing would differ in the two 
main subtypes of MCI relative to cognitively normal subjects, being attenuated in aMCI and amplified in naMCI. 
Our hypothesis drew on diverse research on the neural correlates of cognitive domains, on the neuropathological 
aspects of AD and subcortical ischaemic disease, as well as on the function of specific structures of the CAN, as 
outlined in the section below.
aMCI is defined by episodic memory impairment, which is the hallmark feature of AD and is associated with 
damage to the  hippocampus22, one of the first brain regions affected by neuropathological changes, along with 
the  insula23,24. In subjects with aMCI and AD dementia, atrophy and disrupted functional connectivity of both 
hippocampus and insula have been consistently documented by neuroimaging  studies25–27 and have been found 
to be related to  memory27.
The insula is a key hub within the CAN and a a large body of evidence from animal and human studies cor-
roborates its role in the generation of sympathetic outflow. In rodent models, electrical and chemical stimulation 
of the insula evoked increases in heart rate (HR) and blood pressure (BP)28. In humans, functional neuroimaging 
has shown that, at rest, insular activity negatively correlated with parasympathetic  HRV29,30 and that, during 
tasks eliciting sympathoexcitation, there occurred an activation of the insula which was positively associated 
with muscle sympathetic nerve activity (MSNA)31,32. Likewise, on structural neuroimaging, grey matter volume 
in the insula negatively correlated with parasympathetic  HRV33.
The hippocampus has received less attention as a component of the CAN and, even if retroviral tracing 
techniques have established its connections to the sympathetic  system34, study findings are sparse. However, 
despite some amount of discordance (e.g.32,35), there appears to be growing support for a contribution of the 
hippocampus to sympathetic activation . In animals, chemically-induced epileptiform discharges in the hip-
pocampus increased HR and  BP36 and cholinergic stimulation of the hippocampus increased HRV indices related 
to sympathetic activation/parasympathetic  withdrawal37. Also, the stress response in rodents was characterised 
by an increase in hippocampal electroencephalographic activity which paralleled an increase in HRV indices 
related to sympathetic activation/parasympathetic  withdrawal38, and it was reduced by inhibiting hippocampal 
glutamatergic  transmission39. In humans, functional neuroimaging studies have demonstrated activation of the 
hippocampus during sympathetic  challenges31 as well as negative correlations of parasympathetic HRV with 
hippocampal  activity30 and with the grey matter volume of the parahippocampal  gyrus33. A recent neuroimag-
ing  investigation40 has reported a negative correlation between the activity in the hippocampus and an HRV 
complexity index which decreases with sympathetic  activation41.
In line with these findings, a blunted response to tilt-testing has been reported in subjects with AD  dementia42 
and MCI/AD  dementia21.
We therefore hypothesised that the autonomic response to active standing would be attenuated in aMCI.
naMCI is typified by impairment in non-memory domains such as attention, executive functioning, visuos-
patial skills and language. Attention and executive functioning are well known to be dependent on the integrity 
of prefrontal-subcortical  circuits43 that course through the white matter and are particularly vulnerable to sub-
cortical ischaemic vascular  disease7. A wealth of data from human lesion and neuroimaging studies implicate 
the prefrontal cortex in attention and executive  tasks44,45. Neuroimaging has also revealed atrophy and reduced 
connectivity of the prefrontal cortex in subcortical vascular cognitive  impairment46–48, as well as frontal hypop-
erfusion in dysexecutive  MCI49. White matter damage has been found to predict attention and executive dysfunc-
tion in subjects with cerebral small vessel  disease50, vascular  MCI51,52 and  naMCI53.
A substantial number of works have converged towards the notion of a neurovisceral integration model 
in which the activity of the prefrontal cortex can be taken to to index parasympathetic  function11. In animals, 
eletrical and chemical stimulation of the prefrontal cortex produced a depressor cardiovascular  response54,55. 
In humans, resting parasympathetic HRV has been reported to positively correlate with prefrontal functional 
 connectivity56,57 and with electroencephalographic activation of the prefrontal  cortex58. Parasympathetic HRV 
has been found to covary with task-related changes in prefrontal cerebral blood  flow56 and to increase with 
prefrontal transcranial direct  stimulation59. During sympathoexcitatory manoeuvres, a deactivation of the pre-
frontal cortex has been described which positively correlated with  MSNA31. Higher parasympathetic HRV has 
been associated with greater cortical thickness in prefrontal  regions56 as well as better performance on tests of 
attention and executive  functioning60–64.
Although there is very scant literature addressing the relationship between ischaemic brain damage and HRV, 
it mainly points to a parasympathetic dysfunction with sympathetic predominance. In fact, reduced parasym-
pathetic indices and increased indices of sympathetic activation/parasympathetic withdrawal have been found 
among diabetics with VAD compared to only-diabetic  controls64 and in subjects with obstructive sleep apnea and 
white matter lesions (WML)65 relative to those without WML . Decreased parasympathetic indices have been 
reported in the early stages of Binswanger’s  encephalopathy66, in MCI subjects with  WML67 and in diabetics with 
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lacunar  lesions68. Indices of sympathetic activation/parasympathetic withdrawal have been shown to be higher 
in healthy subjects with lower cerebral  perfusion69.
Since the vagus acts as a "brake" to sympathetic  activation11, we supposed that a parasympathetic deficit would 
lead to unrestrained sympathetic activity during an orthostatic stress. We therefore hypothesised that in naMCI 
subjects there would be an amplified autonomic response to active standing. This would not be at odds with 
findings of a blunted HRV response to tilt in conditions with sympathetic hyperactivity, such as symptomatic 
chronic heart failure and unmedicated  hypertension70 . In fact, an enhanced sympathetic activity already at 
baseline may exhaust the cardiac sympathetic reserve, i.e. it may limit the ability to further increase sympathetic 
activity due to a ceiling effect. However, based on  our20 and others’18,19,21 results, we were not expecting baseline 
differences in HRV indices in MCI subjects, in whom cognitive impairment is slight and dysautonomia is thus 
likely to be subtle. Also, in hyperadrenergic autonomic disorders like orthostatic hypertension and postural 
orthostatic tachycardia syndrome, an increased HRV response to standing has been  described71,72, even in the 
case of sympathetic predominance at  rest71.
In this study, which builds on and extends the data of a previous  study20, we aimed to investigate autonomic 
function by means of power spectral analysis (PSA) of HRV at rest and during an active orthostatic challenge 
in the two main clinical subtypes of MCI: aMCI and naMCI. Cognitively normal (CN) subjects were taken as 
controls. We also sought to explore the relationship of HRV indices with specific cognitive domains, evaluated 
by neuropsychological testing, as well as with structural brain changes, assessed by validated semiquantitative 
visual rating scales.
Results
Table 1 shows the clinical characteristics of the three groups. As expected, scores on the Mini Mental State 
Examination (MMSE), Montreal Cognitive Assessment (MoCA) and Instrumental Activities of Daily Living 
(IADL) were significantly lower in MCI subjects than in controls. The prevalence of hypertension and of use of 
angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACE-I/ARB) was significantly higher 
in the naMCI group. Physical activity was significantly lower in the aMCI group. Trait anxiety, measured by 
the State-Trait Personality Inventory-trait anxiety (STPI-T) scale, was significantly higher in the naMCI group 
although there was no difference between groups in the Visual Analogue Scale (VAS) stress score. All subjects 
had normal blood tests for thyroid function, vitamin B12 and folic acid. None had ischaemic ECG changes, 
pathological ecocardiographic findings (except mild valvular disease) or haemodynamically significant (> 70%) 
carotid stenosis.
Table 2 reports the peripheral vascular burden and the Apolipoprotein E (ApoE) genotypes across the three 
groups. Although carotid intima-media thickness (IMT) and the prevalence of left ventricular hypertrophy 
(LVH) just failed to attain statistical significance, left ventricular mass index (LVMI) and percent plaque were, 
as expected, significantly higher in the naMCI group. ApoE genotyping was available for 55 controls (71% of the 
CN sample) and for all MCI subjects. As expected, the prevalence of carriers of the E4 allele was significantly 
higher in the aMCI group (39%) than in either the naMCI (19%) or CN (15%) group.
Table 3 shows findings from the assessment of cerebrovascular burden, hippocampal atrophy (HA) and insular 
atrophy (IA) on neuroimaging. Computed tomography (CT) scans were available for 34 controls (44% of the 
CN sample) and for all MCI participants except 3 naMCI subjects who refused the exam. Magnetic Resonance 
Imaging (MRI) scans were available for 14 controls (18% of the CN sample) and for just less than two thirds of 
the overall MCI subjects (66% aMCI, 60% naMCI). As anticipated, HA was greater in the aMCI group and deep 
WML (DWML) were more severe in the naMCI group. MRI-based ratings of cerebrovascular burden and HA 
were consistent with the CT findings (Supplementary Table S1).
The CT and MRI scans showed no other pathological findings (e.g. large-vessel disease, subdural haematoma, 
hydrocephalus, tumours). None of the participants had clinical evidence of a cerebrovascular event in the time 
interval between the acquisition of the scan and the autonomic assessment.
The inter- and intra-rater reliability for visual scale ratings on brain neuroimaging were, respectively, excellent 
(Cohen’s weighted kappa  (Kw) 0.83 to 1) and substantial to excellent  (Kw 0.78 to 0.90)73 (Supplementary Table S2), 
and conformed to the  literature74–76.
Table 4 shows the results from the PSA of HRV. The main indices considered were the normalised low 
frequency power (LFn), the low frequency power (LF) to high frequency power (HF) ratio (LF/HF) and HF. 
There were no significant differences across the three groups in baseline LFn, LF/HF and HF. In aMCI subjects, 
compared to naMCI and CN subjects, LFn and LF/HF were significantly lower during active standing and HF 
was significantly higher. Accordingly, Δ LFn and Δ LF/HF were smaller (i.e. less positive) and Δ HF was larger 
(i.e. less negative), although the latter was no longer significant after adjustment for relevant covariates. The 
effect sizes for significant differences in HRV indices were medium to large for LFn and LF/HF (Cohen’s d and 
Glass’s delta between 0.8 and 2.5)77 and medium for standing HF (Cohen’s d = 0.6) (Supplementary Table S3).
In the naMCI group the response to the orthostatic challenge was statistically equivalent to that of the CN 
group. There were no significant differences across groups in the RR interval and in Δ RR.
Total power (TP) showed no statistically significant differences across groups, nor did very low frequency 
power (VLF) and LF (Supplementary Table S4).
Table 5 displays the results of the correlation analyses in the aMCI group. Δ LFn and Δ LF/HF exhibited a 
significant positive correlation with the prose-delayed recall Z-score and a significant negative correlation with 
HA and IA. No significant correlations were found for standing HF.
Table 6 displays the results of the correlation analyses in the naMCI group. Δ LFn and Δ LF/HF exhibited a 
significant negative correlation with the Digit Cancellation test (DCT) and executive functioning Z-scores and 
a significant positive correlation with DWML burden. No significant correlations were found for standing HF.
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Table 1.  Clinical characteristics of the study groups. Continuous variables expressed as mean (standard 
deviation), categorical variables expressed as n (%). ANOVA or Kruskall-Wallis test for continuous variables. 
Chi-squared or Fisher’s exact test for categorical variables. Pairwise comparisons with Bonferroni corrections. 
CN, cognitively normal (controls); aMCI, amnestic mild cognitive impairment; naMCI, non-amnestic 
mild cognitive impairment; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; AU, alcohol units (1 AU = 10 g of alcohol); MET, metabolic equivalent (energy expenditure index, 1 
MET = 1 kcal∙kg−1∙h−1); LDL, low density lipoprotein; HDL, high density lipoprotein; FCVDRP, Framingham 
cardiovascular disease risk profile (score range − 6 to 38, higher scores indicate higher risk); FSRP, 
Framingham stroke risk profile (score range 0–48 , higher scores indicate higher risk); ACE-I, angiotensin 
converting enzyme inhibitors; ARB, angiotensin II receptor blockers; CCB, calcium channel blockers; SSRI, 
selective serotonin reuptake inhibitors; BADL, basic activities of daily living (score range 0–6, higher scores 
indicate greater functional independence); IADL, instrumental activities of daily living (score range 0–8, 
higher scores indicate greater functional independence); MMSE, mini mental state examination (score range 
0–30, higher scores indicate better cognitive function); MoCA, Montreal cognitive assessment (score range 
0–30, higher scores indicate better cognitive function); CIRS-m, cumulative illness rating scale morbidity 
(score range 0–13, higher scores indicate more severe comorbidity); STPI-T, state trait personality inventory-
trait anxiety subscale (score range 10–40, higher scores indicate greater trait anxiety); GDS-s, geriatric 
depression scale short form (score range 0–15, higher scores indicate greater depressive symptoms); VAS, 
visual analogue scale (score range 0–100, higher scores indicate greater stress). a Significant difference between 
aMCI and naMCI, bSignificant difference between aMCI and CN, cSignificant difference between naMCI and 
CN, ***P ≤ 0.001, **P < 0.01, *P < 0.05.
CN (n = 78) aMCI (n = 82) naMCI (n = 93) P-value
Age (years) 78.3 (4.8) 79.5 (5.2) 78.9 (5.5) 0.388
Gender, female 63 (80.8) 56 (68.3) 63 (67.7) 0.113
Education (years) 11.5 (4.4) 10.0 (4.1) 10.3 (4.9) 0.078
BMI (kg/m2) 24.2 (2.9) 25.3 (4.0) 25.2 (3.9) 0.191
Hypertension 41 (52.6) 57 (69.5) 68 (73.1) 0.013c*
SBP (mmHg) 133.9 (16.1) 132.8 (14.7) 131.4 (15.2) 0.749
DBP (mmHg) 75.8 (8.2) 75.0 (7.8) 75.7 (8.0) 0.756
Heart rate, baseline (beats/min) 65.1 (9.0) 65.5 (10.3) 67.4 (9.8) 0.264
Respiratory rate, baseline (cycles/min) 14.5 (2.6) 15.3 (3.2) 15.2 (2.4) 0.136
Respiratory rate, standing (cycles/min) 15.6 (3.0) 16.1 (3.1) 16.5 (2.8) 0.079
Smoking 7 (9.0) 6 (7.3) 6 (6.5) 0.821
Alcohol (AU/day) 1.3 (1.5) 1.0 (1.4) 1.2 (1.4) 0.230
Coffee (cups/day) 1.6 (1.2) 1.2 (1.1) 1.5 (1.1) 0.078
Physical activity (MET-hrs/week) 68.2 (36.9) 52.4 (35.7) 74.1 (45.5) 0.001a**,b*
Glucose (mg/dl) 90.8 (12.1) 91.7 (11.8) 93.3 (10.2) 0.212
Total cholesterol (mg/dl) 219.2 (37.3) 215.2 (39.8) 220.1 (34.6) 0.657
LDL cholesterol (mg/dl) 133.6 (30.9) 131.6 (35.0) 132.1 (27.8) 0.917
HDL cholesterol (mg/dl) 67.3 (19.1) 62.4 (16.0) 64.6 (17.4) 0.258
Triglycerides (mg/dl) 107.8 (43.0) 110.1 (42.7) 107.7 (43.7) 0.863
FCVDRP score 15.8 (3.2) 16.4 (3.3) 16.3 (3.2) 0.405
FSRP score 13.7 (4.2) 14.3 (3.7) 14.5 (4.6) 0.440
Number of medications 3.4 (1.8) 4.3 (2.6) 4.6 (2.6) 0.012c*
Antihypertensive medications
 ACE-I/ARB 31 (39.7) 46 (56.1) 58 (62.4) 0.011c**
 CCB (dihydropyridines) 9 (11.5) 16 (19.5) 19 (20.4) 0.257
 Diuretics 14 (17.9) 23 (28.0) 19 (20.4) 0.271
Psychotropic medications
 SSRI 15 (19.2) 19 (23.2) 30 (32.3) 0.129
 Benzodiazepines 13 (16.7) 12 (14.6) 22 (23.7) 0.270
BADL score 5.4 (0.5) 5.5 (0.6) 5.4 (0.5) 0.059
IADL score 7.4 (1.2) 6.3 (1.5) 6.7 (1.4)  < 0.001b***,c***
MMSE score 28.6 (1.0) 25.8 (2.2) 27.5 (1.9)  < 0.001a***,b***,c***
MoCA score 25.6 (1.7) 21.1 (2.9) 22.9 (2.0)  < 0.001a**,b***,c***
CIRS-m score 2.2 (1.2) 2.1 (1.1) 2.1(1.2) 0.446
STPI-T score 18.5 (5.7) 18.1 (5.0) 20.2 (5.5) 0.016a*
GDS-s score 3.3 (3.0) 3.2 (2.8) 3.8 (2.8) 0.179
VAS-stress score 32.5 (22.1) 26.0 (22.1) 29.7 (23.1) 0.187
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Discussion
To the best of our knowledge this is the first study to investigate autonomic function in the two main clinical 
subtypes of MCI. We hypothesised, based on the neural substrate of cognitive deficits, that the HRV response 
to an orthostatic challenge would be attenuated in aMCI and amplified in naMCI, and chose LFn, LF/HF and 
HF as markers of autonomic activity.
Indeed, in the aMCI group we found a blunted response to active standing, in line with what has been 
described for tilt-testing in MCI/AD  dementia21 and AD  dementia42 subjects. Moreover, we found that this 
response was significantly associated with evidence of functional (i.e. on neuropsychological assessment) and 
structural (i.e. on neuroimaging ) damage to AD-vulnerable brain regions such as the hippocampus and insula. 
In fact, Δ HRV indices correlated (positively) with one episodic memory test (prose-delayed recall) as well as 
(negatively) with visual ratings of atrophy of both the hippocampus (on CT) and insula (on MRI). The lack of 
Table 2.  Peripheral vascular burden and ApoE genotypes in the study groups. Continuous variables expressed 
as mean (standard deviation), categorical variables expressed as n (%). Kruskall-Wallis test for continuous 
variables. Chi-squared or Fisher’s exact test for categorical variables. Pairwise comparisons with Bonferroni 
corrections. CN, cognitively normal (controls); aMCI, amnestic mild cognitive impairment; naMCI, non-
amnestic mild cognitive impairment; LVMI, left ventricular mass index; LVH, left ventricular hypertrophy; 
IMT, intima-media thickness; Carrier, carrying at least one E4 allele. † ApoE genotyping available for n = 55. 
a Significant difference between aMCI and naMCI, bSignificant difference between aMCI and CN, cSignificant 
difference between naMCI and CN, ***P ≤ 0.001, **P < 0.01, *P < 0.05.
CN (n = 78)† aMCI (n = 82) naMCI (n = 93) P-value
Echocardiography
 LVMI (g/m2) 83.3 (15.7) 89.3 (20.4) 97.6 (32.8) 0.002c***
 LVH % 15 (19.2) 19 (23.2) 32 (34.4) 0.061
Carotid ultasound
 IMT (mm) 1.0 (0.1) 1.0 (0.2) 1.1 (0.2) 0.064
 IMT > 0.9 mm 68 (87.2) 66 (80.5) 82 (88.2) 0.308
 Plaque (%) 22.2 (14.6) 21.0 (15.1) 29.6 (12.6)  < 0.001a***,c***
ApoE genotype 0.019
 E2/E3 5 (9.1) 3 (3.7) 6 (6.5)
 E3/E3 42 (76.4) 47 (57.3) 69 (74.2)
 E3/E4 8 (14.5) 29 (35.4) 17 (18.3)
 E4/E4 0 (0) 3 (3.7) 1 (1.1)
 Carrier 8 (14.5) 32 (39.0) 18 (19.4) 0.001a*,b**
Table 3.  Cerebrovascular burden and hippocampal and insular atrophy on neuroimaging in the study 
groups. Scale scores expressed as mean (standard deviation). Kruskall-Wallis test with Bonferroni-corrected 
pairwise comparisons. CN, cognitively normal (controls); aMCI, amnestic mild cognitive impairment; naMCI, 
non-amnestic mild cognitive impairment; PVWML, periventricular white matter lesions (score range 0–3, 
higher scores indicate greater WML load); DWML, deep white matter lesions (score range 0–3, higher scores 
indicate greater WML load); HA, hippocampal atrophy (score range 0–4, higher scores indicate greater HA; 
FI, frontoinsula; IA, insular atrophy (score range 0–3, higher scores indicate greater atrophy). † On CT. ‡ On 
MRI. ¶ CT available for n = 34, MRI for n = 14. ¶¶ CT available for n = 82, MRI for n = 54. # CT available for n = 90, 
MRI for n = 56. a Significant difference between aMCI and naMCI, bSignificant difference between aMCI and 
CN, cSignificant difference between naMCI and CN, ***P ≤ 0.001, **P < 0.01, *P < 0.05.
CN (n = 78)¶ aMCI (n = 82)¶¶ naMCI(n = 93)# P-value
Fazekas’ scale  score†
 PVWML 1.3 (0.5) 1.7 (0.8) 1.4 (0.6) 0.018a*
 DWML 1.2 (0.5) 1.4 (0.6) 1.8 (0.7)  < 0.001a***,c***
Kim’s scale  score†
 Right HA 1.4 (0.8) 2.5 (1.0) 1.4 (0.7)  < 0.001a***,b***
 Left HA 1.7 (0.8) 2.5 (1.0) 1.6 (0.7)  < 0.001a***,b***
 Mean HA 1.6 (0.7) 2.4 (1.0) 1.5 (0.6)  < 0.001a***,b***
FI rating scale  score‡
 Right IA 1.6 (0.6) 2.3 (0.6) 1.6 (0.6)  < 0.001a***,b***
 Left IA 1.5 (0.5) 2.1 (0.6) 1.5 (0.4)  < 0.001a***,b**
 Mean IA 1.6 (0.5) 2.3 (0.6) 1.6 (0.5)  < 0.001a***,b***
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correlation with the other episodic memory test (Rey-Osterrieth Complex Figure (ROCF)-delayed recall) appears 
consistent with research on AD-related cognitive impairment, demonstrating earlier involvement of verbal than 
visual  memory26,27. As far as we aware, the specific association between episodic memory and HRV indices has 
not been previously highlighted in aMCI subjects. Nonetheless, memory recall has been found to correlate with 
parasympathetic HRV (negatively) in a mixed MCI-AD/MCI-LBD sample19, and with HRV indices of sympa-
thetic activation/parasympathetic withdrawal (positively) in an older  cohort13. Also, a negative relationship has 
been reported in late life  depression78 between the quality of episodic memory and TP at rest (which can be 
considered a mainly parasympathetic index)9.
The magnitude of the effect for significant differences in Δ HRV indices between the aMCI group and the 
combined naMCI/CN group was found to be medium to large (Supplementary Table S3) and was, therefore, 
greater than reported for most HRV studies on cognitive  impairment16, in which effect sizes are predominantly 
small and large effects are mainly confined to dementias with severe dysautonomia like  LBD79. The finding that, 
in our study, the effects sizes in aMCI were not small, as is often the case even in full-blown  AD16, is presumably 
Table 4.  Heart rate variability in the study groups. HRV indices expressed as mean (standard deviation). 
Statistical analyses performed on  log10- transformed values except for Δ HF standing (untransformed). CN, 
cognitively normal (controls); aMCI, amnestic mild cognitive impairment; naMCI, non-amnestic mild 
cognitive impairment; n.u, normalised units; LFn, low frequency power (normalised); LF/HF, ratio of low 
frequency power (LF) to high frequency power (HF); Δ standing, standing HRV index—baseline HRV 
index. † ANOVA for all HRV indices except Δ HF standing (Kruskall-Wallis test). ‡ ANCOVA for all HRV 
indices except Δ HF standing (non parametric regression). All post-hoc pairwise comparisons performed 
with Bonferroni correction. Q indicates P-values corrected for multiple testing with the Benjamini–
Hochberg procedure with a 5% False Discovery Rate (FDR). a Significant difference between aMCI and 
naMCI, bSignificant difference between aMCI and CN, ***P ≤ 0.001, **P < 0.01, *P < 0.05.
CN (n = 78) aMCI (n = 82) naMCI (n = 93) P-value† Q P-value‡ Q
RR interval (ms)
 Baseline 938.6 (126.3) 941.5 (166.4) 909.9 (135.5) 0.272 0.466 0.433 0.539
 Standing 875.5 (129.7) 886.8 (151.2) 865.8 (122.2) 0.693 0.751 0.857 0.857
 Δ Standing − 63.1 (74.3) − 54.7 (102.4) − 44.1 (72.1) 0.365 0.505 0.135 0.231
LFn (n.u)
 Baseline 60.5 (16.3) 61.9 (17.2) 59.0 (14.5) 0.751 0.751 0.587 0.640
 Standing 74.8 (13.0) 62.9 (18.5) 76.0 (13.7)  < 0.001a***,b***  < 0.001  < 0.001a***,b***  < 0.001
 Δ Standing 14.3 (10.4) 1.0 (11.6) 17.0 (11.2)  < 0.001a***,b***  < 0.001  < 0.001a***,b***  < 0.001
LF/HF
 Baseline 2.2 (1.8) 2.5 (2.3) 1.8 (1.2) 0.379 0.505 0.308 0.462
 Standing 4.3 (3.3) 2.8 (2.7) 5.0 (4.0)  < 0.001a***,b***  < 0.001  < 0.001a***,b***  < 0.001
 Δ Standing 2.2 (2.3) 0.3 (2.2) 3.2 (3.3)  < 0.001a***,b***  < 0.001  < 0.001a***,b***  < 0.001
HF  (ms2)
 Baseline 201.3 (326.9) 288.1 (529.6) 187.9 (284.0) 0.667 0.751 0.449 0.539
 Standing 87.2 (145.5) 278.0 (575.6) 87.0 (154.9)  < 0.001a***,b***  < 0.001  < 0.001a***,b***  < 0.001
 Δ Standing − 114.1 (254.2) − 10.1 (227.7) − 100.9 (188.5) 0.002a*,b** 0.004 0.102 0.204
Table 5.  Correlations of HRV indices with memory tests and brain atrophy in the aMCI group. Spearman’s 
correlation analysis adjusted for hypertension, physical activity and trait anxiety. Correlations with memory 
scores also demographically-adjusted. Cognitive Z-scores and visual rating scale scores expressed as mean 
(standard deviation). HRV, heart rate variability; aMCI, amnestic mild cognitive impairment; CT, computed 
tomography; MRI, magnetic resonance imaging; LFn, low frequency power (normalised); n.u, normalised 
units; LF/HF, ratio of low frequency power (LF) to high frequency power (HF); Δ HRV index, standing HRV 
index—baseline HRV index; ROCF, Rey-Osterrieth complex figure; HA, hippocampal atrophy; IA, insular 
atrophy. s, standard deviation; r, Spearman’s correlation coefficient; P, adjusted P-value; Q, adjusted P-value 
corrected for multiple testing with the Benjamini–Hochberg procedure with a 5% False Discovery Rate (FDR). 
†On CT. ‡ On MRI.
Mean (s)
Δ LFn (n.u) Δ LF/HF HF standing (ms2)
r P Q r P Q r P Q
Prose delayed recall (Z-score) − 2.32 (1.36) 0.298 0.009 0.025 0.296 0.009 0.025 0.052 0.653 0.712
ROCF-delayed recall (Z-score) − 1.64 (0.61) 0.185 0.109 0.187 0.121 0.297 0.396 0.136 0.241 0.362
Mean HA  score† 2.4 (1.0) − 0.331 0.003 0.017 − 0.331 0.003 0.017 0.027 0.816 0.816
Mean IA  score‡ 2.3 (0.6) − 0.358 0.011 0.025 − 0.326 0.021 0.042 − 0.071 0.625 0.712
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due to the fact that we used an orthostatic stressor which can enhance the sensitivity of HRV analysis for auto-
nomic dysfunction.
On the contrary, in the naMCI group we were unable to find the amplified response to active standing we had 
theoretically anticipated: while the postural changes in HRV indices (LFn and LF/HF) were increased relative 
to controls, they were not significantly so. However, on correlation analyses we found that Δ HRV indices were 
associated (negatively) with one attention test (DCT) and with a composite measure of executive functioning as 
well as (positively) with DWML. No such associations were found in CN subjects .The finding that naMCI sub-
jects had the same response to orthostatic stress as CN subjects is likely due to the fact that the exclusion criteria, 
inherent to a study on the cerebral substrate of HRV (see “Methods”), selected a low/intermediate cardiovascular 
risk population in which severe brain vascular burden was under-represented, thus reducing our ability to detect 
a significant effect. In particular, most studies demonstrating autonomic dysfunction in ischaemic brain damage 
have focused on subjects at high cardiovascular risk like diabetics  with64 and  without68 VAD as well as patients 
with obstructive sleep  apnea65, or have not excluded individuals with cardiovascular risk factors and  diseases67. 
In our naMCI group at low/intermediate cardiovascular risk, a provocative manoeuvre such as paced breath-
ing, which challenges the parasympathetic  system80, could have directly assessed the parasympathetic reserve 
and unmasked mild parasympathetic deficits. However, we decided not to use it because of its potential for bias 
(see “Methods”). Nevertheless, it should be noted that the correlations observed in the naMCI group were in 
the expected direction, i.e., they argue in favour of the notion of a parasympathetic deficit causing sympathetic 
hyperactivation. In fact, indices of sympathetic activation/parasympathetic withdrawal were higher in subjects 
with poorer performance on tests of frontal lobe function and with more extensive subcortical vascular damage. 
The lack of correlation with one of the two attention tests (Bell Test) is probably a a consequence of the more 
restricted score range, which decreases the likelihood of identifying a significant association.
In both the aMCI and naMCI groups, significant correlations of Δ HRV indices with cognitive tests and 
structural brain changes were small in term of effect sizes (r < 0.3)81. This result is commensurate with other 
studies on resting HRV and cognitive tests in more varied samples (e.g.60–62). It is conceivable that, in our case, 
the ability of an orthostatic challenge to highlight stronger associations was offset by greater sample homogeneity.
There were no significant differences across groups in other HRV indices (mean RR interval, TP, LF and VLF) 
(Supplementary Table S4).
The lack of significant differences in the the RR and Δ RR intervals is worthy of specific comment and could 
be due to different reasons. First, HRV is a more reliable estimator of autonomic function than  HR82 and has 
proved to be more sensitive in detecting subtle dysautonomia across a range of  diseases83–85. Indeed, there are 
numerous reports of no difference in the HR response to an orthostatic challenge in subjects with MCI or even 
AD dementia (e.g.21,86,87). Second, in our study the standing HR (and HRV) was determined from an ECG seg-
ment between the 5th and 10th minute of active standing. Since the time course of HR reactivity to standing is 
characterised by a HR peak at around 10 s and a HR nadir at around 30 s with subsequent stabilisation of HR to 
values higher than  baseline88, our protocol was not designed to capture the maximum postural Δ RR and could 
be missing potentially meaningful differences in RR intervals across the three groups. Third, it can be speculated 
that in aMCI subjects, the finding of a significant difference in Δ HRV coupled with no difference in Δ RR, could 
be indicating impaired baroreflex function. However, confirmation of such hypothesis would have required 
continuous BP monitoring (see Limitations).
The clinical, neuropsychological and vascular burden characteristics of the study subjects were consistent 
with AD neurodegeneration and vascular cognitive impairment in the aMCI and naMCI groups respectively. 
They are discussed in the Supplementary Discussion.
Our study has some limitations. Although the use of transformed HRV indices (LFn and LF/HF) finds support 
in the literature (see “Methods”), it has also been questioned (e.g.89). In particular, changes in LFn and LF/HF 
have been mainly ascribed to changes in HF, implying that transformed indices are not markers of sympathetic 
activity but rather of parasympathetic  withdrawal89. However, it is generally recognised that orthostatic stress 
induces a reciprocal pattern of sympathetic/parasympathetic  change90 and the conceptual framework of the 
neurovisceral integration model involves autonomic  reciprocity11. Also, despite the fact that LFn and LF/HF 
Table 6.  Correlations of HRV indices with attention and executive tests and cerebrovascular burden in the 
naMCI group. Spearman’s correlation analysis adjusted for hypertension, physical activity and trait anxiety. 
Correlations with DCT and executive scores also demographically-adjusted. Cognitive Z-scores and visual 
rating scale scores expressed as mean (standard deviation). naMCI, non-amnestic mild cognitive impairment; 
LFn, low frequency power (normalised); n.u, normalised units; LF/HF, ratio of low frequency power (LF) to 
high frequency power (HF); Δ HRV index, standing HRV index—baseline HRV index; DCT, digit cancellation 
test; DWML, deep white matter lesions. s, standard deviation; r, Spearman’s correlation coefficient; P, adjusted 
P-value; Q, adjusted P-value corrected for multiple testing with the Benjamini–Hochberg procedure with a 5% 
False Discovery Rate (FDR). † On CT.
Mean (s)
Δ LFn (n.u) Δ LF/HF HF standing (ms2)
r P Q r P Q r P Q
Bell Test (Z-score) − 3.06 (3.95) − 0.110 0.300 0.400 0.078 0.463 0.505 − 0.069 0.519 0.519
DCT (Z-score) − 0.28 (0.68) − 0.274 0.010 0.024 − 0.309 0.004 0.022 0.080 0.460 0.505
Executive functions (Z-score) − 0.99 (0.54) − 0.257 0.016 0.032 − 0.339 0.001 0.016 0.161 0.136 0.204
DWML score† 1.8 (0.7) 0.277 0.009 0.024 0.274 0.010 0.024 − 0.168 0.119 0.204
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have been somewhat inconsistently associated with  MSNA89, they have been shown to exhibit strong positive 
correlations with the  normalised91 and  absolute92 LF powers of MSNA variability during tilt. In our study, it 
would thus appear appropriate to interpret LFn and LF/HF as indices of sympathetic activation/parasympathetic 
withdrawal. Moreover, even if our findings fit in nicely with the role of CAN components (insula, hippocam-
pus and prefrontal cortex) in autonomic control, as outlined in the Introduction, alternative inferences can be 
made should one focus only on the notion of parasympathetic withdrawal, albeit during a manoeuvre designed 
to activate the sympathetic nervous system . For instance, it might be speculated that lesser parasympathetic 
deactivation in aMCI stems from deficits of the cholinergic system in  AD93. Likewise, greater parasympathetic 
deactivation in naMCI could be due to vagal hyperreactivity secondary to ischaemic damage. In fact, because of 
the exclusion criteria, subjects with naMCI could be at a prior stage of the disease than those with aMCI, and a 
compensatory response has been described in early  MCI26. Anyhow, our results would still provide evidence for 
differential autonomic impairment in the two clinical subtypes of MCI.
Finally, it must be acknowledged that HF, unlike tranformed indices, is not limited by the assumptions of 
reciprocity and  linearity89,94. Yet, the only significant difference we found across groups was in standing HF, and 
standing HF was not significantly correlated with cognitive tests or structural brain damage in the aMCI and 
naMCI groups. This was probably the case because HF is a highly dispersed  variable95. It is possible that different 
results could have been obtained with a PSA software based on the Welch method, since averaging windowed 
periodograms has been shown to effectively reduce  variance96. Similarly, even if traditional HRV indices are 
recommended as the mainstay of HRV analysis, non-linear measures, which are still not implemented in com-
mercial devices like the one we used, might have provided additional information on the  ANS97 .
The unavailability of non invasive beat-to-beat BP monitoring precluded the assessment of baroreceptor 
 function98, thus leaving a promising avenue of research unexplored. In fact, despite substantive evidence of bot-
tom-up modulation of cortical activity by the central nervous branch of the baroreceptor as well as of top-down 
influences of rostral brain units on the baroreflex loop, studies on baroreflex sensitivity in cognitive impairment 
are  scarce99. Also, findings are inconsistent, with both  decreased100 and  unchanged21,87 baroreflex sensitivity 
reported in AD-related MCI and dementia.
The lack of more sophisticated software, operating in conjunction with respiratory signal recording, may have 
restricted the number of cases suitable for PSA. As recommended, we excluded subjects with a respiratory rate 
outside the range of the HF  band101. Although only very few individuals were lost to analysis (n = 1 in the previ-
ous and n = 4 in the current study), such limitation could have been overcome by approaches that centre the HF 
band around the respiratory frequency (when respiratory rate is > 24 breaths/min)102 or that decompose the LF 
band in respiratory and non-respiratory components (when respiratory rate is < 9 breaths/min)103.
The two main clinical subtypes of MCI were assumed to have different underlying aetiologies (AD for aMCI 
and subcortical small-vessel disease for naMCI) based on well established data from the literature (see “Introduc-
tion”), but the diagnosis of MCI due to AD was not confirmed by research biomarker criteria like CSF measures 
and/or amyloid or perfusion/metabolism  neuroimaging1. It might be argued that aMCI of the multiple-domain 
type could represent the longitudinal outcome of both AD and vascular brain  damage104, and that naMCI could 
be associated with non-vascular  aetiologies1. However, several issues deserve mention. First and foremost, find-
ings regarding vascular burden and HA on CT scans as well as the genetic risk of AD (see “Results”) lended sup-
port to our hypothesis. In particular, the 39% prevalence of ApoE4 carriers in the aMCI group is very much in 
line with the 40% value reported for  AD105. Second, it appears reasonable to  posit4,5 that multiple-domain aMCI 
is most likely to progress to AD rather than VAD. In fact, AD is more  frequent7, has a faster rate of  decline106 and 
affects memory and other cognitive domains at an early  stage107, while memory impairment has been shown to 
develop late in the course of subcortical vascular  disease108. This would hold particularly true in a sample like ours 
at low/intermediate cardiovascular risk. Third, we considered older subjects and used psychiatric and neurologi-
cal disorders as exclusion criteria, so non-AD related neurodegeneration is unlikely to be relevant in the naMCI 
group. Indeed, LB pathology is accompanied by visual hallucinations and  parkinsonism109, and prodromal FTD 
is young-onset and often presents with behavioural (i.e. psychiatric-like)  symptoms110. Fourth, atypical non-
amnestic variants of AD and mixed AD/vascular processes cannot be ruled out, but the former are  rare111 and 
there is evidence that the latter are dominated by AD  neuropathology112. Fifth, there may be several downsides 
to biomarkers including invasiveness, limited accessibility and the possibility of their being uninformative (i.e. 
ambiguous or conflicting) in a substantial proportion of MCI  subjects113.
The main neuroimaging tool in our study was CT, since all MCI subjects were prescribed a brain CT scan as 
part of the routine diagnostic work-up (n = 172) while not all had a brain MRI scan (n = 110), so that focusing 
on MRI would have required us to reduce the study sample by about 40%. Although CT has practical advantages 
over MRI, which explain its widespread use in clinical settings, MRI is considered the gold standard for detecting 
structural brain changes, especially those related to small-vessel  disease114. Still, the two neuroimaging tech-
niques gave similar results across groups (see Supplementary Table S1 for MRI-based ratings of cerebrovascular 
burden and HA) and correlations of Δ HRV indices with visual scores of HA and DWML were not significantly 
different on CT and MRI scans (for all, p > 0.7 with Fisher’s r to z transformation test, Supplementary Table S5). 
In addition, even if MRI would have enabled brain volumetry, visual rating scales have several strengths. They 
are simpler and less time intensive and can be applied to both CT and  MRI115. They have been validated against 
volumetric measures, with which they are strongly  correlated76,115,116, and exhibit substantial to excellent repro-
ducibility, in the literature and in our specific sample (see “Results”). HA visual rating scales, compared to volu-
metry, have been shown to be  better117,118 in discriminating CN from MCI and AD dementia subjects, and to 
be more accurate predictors of memory performance in community-dwelling older people across the cognitive 
 spectrum117,119. This is possibly so because visual inspection encompasses not only the hippocampus, but also 
the surrounding perihippocampal space, which reflects atrophy of other AD-targeted brain regions such as the 
parahippocampal  gyrus120.
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As to the possible selection bias arising from the fact that neuroimaging, in particular MRI, was unavail-
able for some of the subjects (see “Results”), as well as from the fact that MoCA screening was preliminary to 
neuropsychological testing only in the current enrollment (see “Methods”), it has been addressed by subgroup 
analyses (Supplementary Table S6–S8) and found to be unlikely to hamper the validity of the Results, as reported 
in the Supplementary Discussion .
The use of exclusion criteria may limit the generalisability of our findings to the overall MCI population. 
Also, although the enrollment of subjects with incident (i.e. newly diagnosed) MCI avoids survival  bias121, the 
cross-sectional design of the study prevents causal inference. Longitudinal studies will therefore be needed to 
elucidate the direction of the relationship between cognitive and autonomic dysfunction, as well as to confirm 
the predictive value of autonomic impairment for adverse events like falls/syncope, progression to dementia, 
and all-cause and cardiovascular mortality.
In conclusion, our findings substantiate the view that the ANS is differentially impaired in the two subtypes 
of MCI, in keeping with the neuranatomic substrate of AD and small-vessel subcortical ischaemic disease. In the 
aMCI group there was a blunted autonomic response to standing. Within the naMCI group functional (i.e. on 
neuropsychological testing) and structural (i.e. on neuroimaging) cerebrovascular damage was associated with an 
increase in the autonomic response to standing. These results contribute novel insight into autonomic modulation 
in MCI and hold potential clinical relevance as autonomic assessment could eventually help to identify subjects 
at higher risk of adverse health outcomes to whom interventions should be targeted.
Methods
Study population. In this cross-sectional study we considered for inclusion 819 community-dwelling older 
subjects (aged ≥ 65) who consecutively attended a first geriatric visit at the Geriatric Outpatient Unit of our hos-
pital, from January 2016 to September 2017. Referrals were made by general practitioners (GPs) for a wide spec-
trum of age-related health problems. 120 subjects with a known diagnosis of dementia were excluded, while the 
remaining 699 were assessed for eligibility by applying a number of exclusion criteria (see later). We thus identi-
fied 292 eligible subjects who were screened for cognitive impairment by means of the  MoCA122. The 228 who 
screened positive (MoCA score < 26) were invited to undergo neuropsychological testing. Of the 223 subjects 
who agreed to neuropsychological testing, 34 were diagnosed with dementia and were excluded. The remain-
ing 189 subjects, with a diagnosis of MCI or normal cognition (CN), were asked to take part in the autonomic 
assessment. Of these 6 declined, so 183 subjects underwent the autonomic assessment and recordings from 173 
(n = 62 aMCI, n = 73 naMCI, n = 38 CN) were ultimately considered, after 10 were excluded (see HRV analysis).
Our study includes data from the currently enrolled 173 subjects as well as data from 80 subjects (n = 40 MCI, 
n = 40 CN) enrolled in a similar, previous  study20.
All subjects who accepted the autonomic assessment were also given an ad hoc clinical assessment. All 
MCI subjects were prescribed a brain CT scan and ApoE genotyping as part of the routine diagnostic work-up 
for cognitive impairment at our Unit. CN subjects were offered ApoE genotyping as part of ongoing research 
 protocols123. For all subjects a standard blood panel was requested (including blood count, glycaemia, lipid profile, 
kidney and thyroid function, vitamin B and folic acid). Brain CT scans were not prescribed to CN subjects and 
brain MRI scans were prescribed to MCI subjects by the geriatrician on a case-by-case clinical basis. However, 
neuroimaging data were also evaluated for those CN subjects who had for some reason (Supplementary Table S9) 
undergone a brain CT or MRI, and for MCI subjects who had undergone an MRI scan.
Brain neuroimaging was considered only if performed in the previous 6 months. The clinical and autonomic 
assessments were carried out within one month from the neuropsychological assessment. HRV recordings and 
brain scans were obtained with the same machines (see later) in the two enrollments.
The rationale for the use of the MoCA as a preliminary screening tool only in the current enrollment is dis-
cussed in the Supplementary Methods.
The study was conducted in accordance with the Declaration of Helsinki and was approved by the ethics 
committee of the Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico in Milan, Italy. All participants 
gave written informed consent to participation in the study.
The study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 
guidelines for cross-sectional  studies124.
exclusion criteria. Briefly, exclusion criteria were clinical conditions and medications with an established 
and significant effect on HRV. They have been previously detailed and  referenced20 and are listed in the Supple-
mentary Methods. It may be appropriate to remark here that, given that the aim of the study was to investigate 
HRV changes due to cerebral disease, non-cerebral conditions influencing HRV (including some cardiovascular 
risk factors and all cardiac diseases) were among the exclusion criteria; this methodological premise will inevi-
tably select a sample at low/intermediate cardiovascular risk (see “Discussion”). It is also worth noting that, even 
though stroke is a potential cause of vascular cognitive impairment, we chose to exclude subjects with a history 
of stroke because their cognitive profile is very heterogeneous, depending on lesion  location7, and they more 
often present with overt  dementia8. We preferred to focus on subcortical vascular disease which, besides being 
more prevalent and more often preceded by MCI, is also characterised by a clinically homogenous phenotype 
dominated by attention and executive  deficits7,8.
neuropsychological assessment. The neuropsychological assessment was carried out by means of a 
comprehensive battery of tests investigating different cognitive domains. The neuropsychological tests and their 
references can be found in Supplementary Tables S10 and S11.
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In particular, among tests of episodic memory, we chose measures of delayed recall since they have been 
shown to have the greatest diagnostic accuracy in identifying the earliest cognitive changes of  AD125.
MCI was diagnosed according to current consensus criteria of objective cognitive impairment on neuropsy-
chological testing, essentially preserved daily functioning (i.e. intact basic activities of daily living (BADL) with 
no or minimal impairment of instrumental activities of daily living (IADL)) and no  dementia1.
A cognitive domain was considered to be impaired if at least one test within that domain was impaired and 
MCI was classified in aMCI and naMCI based on the presence or absence of impairment in the episodic memory 
domain. Further subcategorisation in single- versus multiple-domain MCI was made for descriptive purposes 
only (Supplementary Table S12).
Further information on the diagnosis of MCI is given in the Supplementary Methods.
clinical assessment. All subjects received a full clinical assessment during which we collected general 
clinical information, as well as data on vascular risk and peripheral (i.e. non-cerebral) vascular burden. The 
former included composite vascular risk scores and the latter corresponded to the echographically-determined 
target organ damage (carotid atherosclerosis and LVH).
A more detailed description of the clinical assessment can be found in the Supplementary Methods.
Assessment of cerebral vascular burden and atrophy. CT imaging was performed on a 64-slice CT 
scanner (OptimaCT660, GE Healthcare, Milwaukee, WI; tube voltage 120 KVp, tube current 150–350 mA with 
automatic modulation, slice thickness 0.625 mm, field of view (FOV) 250 × 250  mm2, matrix size 512 × 512). 
MRI was performed on a 3-T scanner (Achieva, Philips Medical Systems, Eindhoven, the Netherlands) using a 
standard acquisition protocol including the following sequences: (a) T1-weighted (relaxation time (TR) 9.9 ms, 
echo time (TE) 4.6 ms, flip angle (FA) 8°, slice thickness 1 mm , slice gap 0, FOV 240 × 240  mm2, matrix size 
240 × 240), (b) T2-weighted turbo spin echo (TSE) (TR 2,491  ms, TE 77  ms, FA 90°, slice thickness 4  mm, 
slice gap 0, FOV 230 × 230  mm2 , matrix size 505 × 512), (c) Fluid-attenuated inversion recovery (FLAIR) (TR 
11,000 ms, TE 125 ms, FA 90°, slice thickness 4 mm, slice gap 0, FOV 230 × 230  mm2, matrix size 249 × 344).
Cerebrovascular burden and atrophy of the insula and hippocampus were assessed on CT and MRI brain 
scans by means of standard semi-quantitative visual rating scales. DWML and periventricular white matter 
lesions (PVWML) were evaluated by means of a slightly modified version of Fazekas’  scale74, scored on axial CT 
scans and on axial FLAIR MRI scans. Due to the acknowledged vascular (i.e. ischaemic) aetiology of DWML 
(see Supplementary Methods) the DWML score was used in the correlation analyses. HA was rated by means of 
Kim’s 5-point  scale126 on axial CT and axial T1-weighted MRI scans and by means of Scheltens’ 5-point  scale127 
on coronal T1-weighted MRI scans. HA was rated separately for the right and left hemispheres and the average 
HA score was used in the correlation analyses since this measure has been shown to be particularly sensitive 
to  AD128. IA was assessed on coronal T1-weighted MRI scans by means of the 4-point frontoinsula (FI) rating 
 scale76, which was rated separately for the right and left hemispheres and then combined in an overall average 
score for use in the correlation analyses. All these scales are described in detail in the Supplementary Methods.
A single trained rater evaluated the anonymised scans of all participants. To provide independent validation of 
the visual ratings scored by the primary rater, a second rater, with expertise in the neuroradiological assessment 
of cognitive impairment, rated a random sample of brain scans (n = 50 CT, n = 50 MRI) from which inter-rater 
reliability was calculated . The primary rater also re-rated this subset of scans in order to compute intra-rater 
reliability. To improve rating consistency, raters were supplied with reference images of specific anatomic land-
marks and illustrative examples of each rating scale. Ratings from the primary rater were used in the analyses. 
The assessment of reliability is illustrated in the Supplementary Methods.
Because of the clinical context of the study, although the vast majority of subjects underwent on-site neuro-
imaging, a very small number (n = 20: n = 7 aMCI, n = 10 naMCI and n = 3 CN) were scanned at other hospital 
sites due to personal logistical reasons. However, their neuroimaging data were acquired and included in the 
study since it is acknowledged that visual rating scales are robust to scanner differences (e.g.129).
The main neuroimaging tecnique in our study was CT, since CT brain scanning was performed in all MCI 
subjects. MRI scans were used to assess IA (since this was not possible on our conventional CT scans lacking 
coronal reconstructions) and in order to provide a gold-standard comparison with CT ratings of cerebrovascular 
burden and hippocampal atrophy (see “Discussion”).
Apoe genotyping. Blood samples were drawn after at least 6 h of fasting and the ApoE genotype was deter-
mined, as described  elsewhere123. Subjects were classified as ApoE4 carriers if they had at least one ApoE4 allele.
Autonomic assessment. The autonomic assessment was carried out as previously  described20. It was per-
formed in a quiet room, with dimmed lighting and a comfortable temperature (22–24 °C), between 8:30 and 
11:30 a.m. in order to minimise the effect of circadian changes in HRV. Participants were instructed to con-
sume a light breakfast and refrain from caffeinated beverages, alcohol, smoking and vigorous physical activity 
in the 12 h prior to testing. After a standard 12-lead ECG, three-channel ECG recordings for HRV analysis were 
obtained by means of a digital Holter recorder (Spider View, Sorin Group Company).
The protocol was composed of two stages. The first (baseline) consisted of supine rest with free breathing: 
15 min during which the subjects were asked to remain awake, silent and still, breathing spontaneously. The sec-
ond (sympathetic stimulation) corresponded to an active standing manoeuvre: 10 min during which the subjects 
were asked to remain still and silent, breathing spontaneously, after standing upright in as smooth a motion as 
possible. To allow for stabilisation, only the last 5 min of each stage were analysed.
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The spontaneous respiratory rate can be assessed by the peak frequency of the HF band on PSA (5-min aver-
age), but, for greater accuracy, it was also visually monitored (over five contiguous one-minute periods). Subjects 
with a respiratory rate < 9 breaths/min (< 0.15 Hz) or > 24 breaths/min (> 0.40 Hz) were excluded, due to the shift 
of the high frequency band which precludes proper interpretation of  PSA101.
BP was recorded at the end of the baseline period using a validated digital spyghmomanometer over the 
brachial artery (OMRON M6).
At the end of the protocol participants were asked to rate their level of stress on a VAS scale from 0 (no stress) 
to 100 (maximum stress), since emotional stress can affect  HRV9.
Unlike in our previous  work20, we decided not to include in the protocol a stage of paced breathing at 12 
breaths/min (parasympathetic stimulation)80. We are aware that a parasympathetic challenge could have pro-
vided more sensitive and direct information on the functioning of the parasympathetic nervous system, which 
would have been particularly valuable in our sample of naMCI who exhibit low/intermediate vascular risk (see 
“Exclusion criteria” and “Discussion”) and are thus likely to have mild frontal lobe vascular damage and slight 
parasympathetic dysfunction. Nevertheless, we chose to omit it because we believed it would introduce an 
intrinsic bias in the study. In fact, based on evidence of a strong relationship of higher-level complex everyday 
activities with executive  functions130 and subcortical white matter  damage131, it was reasonable to suppose that 
naMCI participants would have greater difficulty in correctly performing a cognitively demanding task like 
synchronising their breathing rhythm with pre-set acoustic signals from a metronome. Indeed, even if the 
appearance of a 0.2 Hz peak within the HF spectrum gives a rough confirmation that an individual has achieved 
the target respiratory rate within the 5-min analysis, it cannot rule out interference from short-term fluctuations 
in respiratory frequency.
HRV analysis. HRV analysis was performed in the frequency domain (PSA) on 5-min ECG recordings 
from each of the two stages (baseline and active standing), in accordance with standard  guidelines10. We used 
commercial software (Synescope version 3.10, Sorin Group Company) which conducts PSA by means of the Fast 
Fourier Transform (FFT), after linear interpolation/resampling at 4 Hz of the discrete event series (to obtain a 
regularly time-sampled signal) and filtering with a Hanning window (to attenuate leakage effects)20. The software 
corrects for ectopics by linear interpolation based on the surrounding sinus  beats9. Although the software auto-
matically detects non-sinus beats, the recordings were always manually overread by an experienced investigator, 
blinded to the subject’s cognitive status, in order to ensure correct QRS complex classification and rhythm iden-
tification. Since there is no clear indication in the literature as to the amount of ectopic beats that it is acceptable 
to remove or remove and interpolate, we chose the most restrictive criterion of 1% of the total number of  beats20. 
Therefore, recordings with excessive supraventricular or ventricular ectopy (i.e. ectopic beats > 1% of total beats) 
were excluded from analysis, as were those with other arrhythmias.
PSA can yield several different indices: VLF (≤ 0.04 Hz), LF (0.04–0.15 Hz), HF (0.15–0.4 Hz), TP (≤ 0.4 Hz), 
LFn, normalised HF (HFn) (corresponding respectively to LF/(LF + HF) × 100 and HF/(LF + HF) × 100) and the 
LF/HF  ratio9 .
We chose to focus on LFn, the LF/HF ratio and HF as markers of autonomic function because other indices 
cannot be meaningfully interpreted. TP only quantifies overall autonomic  modulation9. The nature of LF is 
highly controversial and it has been taken to reflect prevalently sympathetic  modulation9, mixed sympathetic 
and parasympathetic  modulation9, and predominantly parasympathetic  modulation89. VLF is best evaluated 
over 24 h132 and its physiological underpinnings are still under  discussion133. HFn was not included in the results 
since it is specularly correlated to LFn (given that they add up to a 100).
Although tranformed measures (LFn, HFn and the LF/HF ratio) have received ample support (e.g.70,134,135) 
and are extensively used in HRV studies across topics (e.g.136-138), they also suffer from limitations (e.g.89,94) 
which have been addressed in the Discussion. Within the context of autonomic reciprocity, LFn and the LF/HF 
ratio can be viewed as indices of sympathetic activation/parasympathetic withdrawal. HF is an acknowledged 
marker of parasympathetic  activity9,101.
In particular, the changes of LFn, the LF/HF ratio and HF from baseline to active standing, assessed by Δ HRV 
indices (active standing measure—baseline measure) are especially sensitive markers of autonomic modulation 
because they directly quantify the response to orthostatic stress and explore the dynamic range of the  ANS70.
Of the 183 subjects undergoing autonomic assessment 10 were excluded from HRV analysis (n = 4 for respira-
tory rate, n = 6 for excessive ectopic beats).
Statistical analysis. Data are reported as mean (standard deviation) for continuous and ordinal variables 
and as number (percentage) for categorical variables. The normality of the data was assessed by using the Sha-
piro–Wilk test. HRV indices were normalised by logarithmic transformation to base 10 (lg), except for Δ HF 
which could not be normalised by transformations. The three groups were compared on categorical variables 
by means of the Chi-squared test or Fisher’s exact test, and on continuous (and ordinal) variables by means of 
One-Way Analysis of Variance (ANOVA) or the Kruskall-Wallis test, as appropriate. All post-hoc pairwise com-
parisons were conducted with Bonferroni corrections. Analysis of Covariance (ANCOVA) was used to compare 
the three groups on HRV measures while controlling for potential confounders, which were chosen among the 
variables found to be significantly different across the groups, i.e. prevalence of hypertension, levels of physical 
activity and the STPI-T score. Use of ACE-I/ARB medications and the Cumulative Illness Rating Scale-morbid-
ity (CIRS-m) score were not included in the ANCOVA in order to avoid loss of power due to multicollinearity 
since these variables were found, as expected, to be redundant with the prevalence of hypertension (Cramer’s 
V = 0.774 and Eta squared = 0.209 respectively). For Δ HF a non parametric alternative to ANCOVA was used, 
i.e. rank-based regression (Rfit) from the "npsm" package in  R139.
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The relationship of autonomic function with relevant measures of cognition and of structural brain changes 
in each of the two MCI groups (aMCI and naMCI) was investigated by means of Spearman’s correlation analysis, 
adjusted for prevalence of hypertension, levels of physical activity, STPI-T score and, in the case of measures 
of cognition, also demographics. Autonomic function was indexed by the HRV measures which were found 
to be significantly different across groups (Δ LFn, Δ LF/HF and standing HF); measures of cognition were the 
Z-scores for tests of memory (aMCI) as well as of attention and executive functioning (naMCI); measures of 
structural brain changes were the CT-based Fazekas’ DWML (naMCI) and Kim’s HA (aMCI) scores as well as 
the MRI-based FI rating score (aMCI). With regard to measures of cognition, we chose to compute a composite 
score for executive function, evaluated by as many as nine tests, to minimise the likelihood of type I error asso-
ciated with multiple testing. Individual test scores were standardised by conversion to Z-scores and the average 
of the Z scores was taken to be the domain-specific Z-score. Z-scores for each test were calculated as (test score 
subject—mean score norm group)/standard deviation norm group, by using the mean and standard deviation of 
published normative data for raw scores (references available in Supplementary Table S10). Scores that quantified 
response time (i.e. Trail-Making Tests A and B ) or number of errors (i.e. Cognitive Estimates Total and Bizarre) 
were first multiplied by -1, so that negative Z-scores always indicated poor performance. For the sake of con-
sistency and for ease of comparison, Z-scores were also generated in the same manner for each of two memory 
tests (prose-delayed recall and ROCF-delayed recall) and each of two attention tests (Bell Test and DCT). Since 
Z-score standardisation was based on normative data for the raw (i.e. non demographically-corrected) scores, 
demographics (i.e. age, gender and education) were also adjusted for in the correlation analyses, except for the 
Bell Test which requires no demographic adjustment (see relevant references in Supplementary Table S10).
To address the issue of inflation of type I error due to multiple comparisons between variables, we employed 
the Benjamini–Hochberg  procedure140 with the False Discovery Rate (FDR) set at the conventional level for alpha 
(5%). This was preferred to the Bonferroni correction because the latter is known to be overly conservative in 
the case of highly correlated variables, like ours, leading to an undue loss in statistical power (i.e. an increase in 
false negatives), which would be inappropriate also given the exploratory nature of the  study141.
The effect sizes for differences in HRV indices were calculated by comparing the aMCI group with the 
naMCI and CN groups, which were collapsed into a single group since they showed no significant differences 
in the autonomic response to standing. For the independent samples t-test, we used Cohen’s d or Glass’s delta 
depending on whether the assumption of homogeneity of variance was satisfied (as assessed by Levene’s test)142. 
For Mann–Whitney’s U-test, we  used143 the correlation coefficient r. Effect sizes are reported in full in Supple-
mentary Table S3.
Based on our previous finding of at least medium effect  sizes20 and according to current guidelines for HRV 
 studies77, we estimated that a minimum sample size of around 60 subjects per group would be required to achieve 
80% statistical power at a 5% alpha level. Hence, our recruitment of more than 70 participants per group met 
(and exceeded) this minimum sample size recommendation.
A P value ≤ 0.05 was considered statistically significant. Analyses were performed by means of the statisti-
cal packages SPSS version 25.0 (SPSS Inc., Chicago, IL) and R version 3.5.2 (The R Foundation for Statistical 
Computing, Vienna, Austria) for Windows.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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